Physical data specialist Salted has gained recognition for its global competitiveness in the rapidly expanding smart insole market.
Salted announced Wednesday that it was cited as a leading company in the smart insole market in the latest report by global market research firm Market Report Analytics (MRA).
In the report, MRA projected the global smart insole market will expand from $800 million in 2024 to $2.5 billion by 2028, with a compound annual growth rate (CAGR) exceeding 20%. The firm noted that the market, previously concentrated in sports applications, has entered a growth phase driven by expanding healthcare monitoring demand, advances in sensor and data analytics technology, and trends toward remote monitoring and preventive medicine. MRA identified six leading players in the smart insole market: Salted, Germany's Moticon, U.S.-based Smartfoam, China's Foamwell, Canada's Orpyx, and India's Ducere. The report predicted strategic alliances and mergers and acquisitions will become more active in the near future.
According to Salted, smart insoles are evolving beyond simple accessories into next-generation wearables that precisely collect and interpret physical data such as gait and movement. The company noted that as artificial intelligence advances, the importance of technology capable of capturing high-quality physical data from the real world is increasing, with smart insoles expected to play a pivotal role.
Salted was established in 2015 as a first-generation spin-off from Samsung Electronics' in-house venture program C-Lab. Over the past decade, the company has accumulated more than 50,000 real-world physical data records in medical and sports markets based on its foot pressure measurement technology using smart insoles. Recently, Salted has been expanding its influence in the digital healthcare market with "Neurogate," a medical device that comprehensively analyzes gait, balance, and lower extremity function using AI technology. Neurogate prescriptions grew from 53 cases in January 2025 to more than 1,000 monthly prescriptions within approximately one year. The device was newly adopted by more than 40 medical institutions nationwide over the past year, rapidly expanding its use in the medical market. This year, the company will begin preparations for an initial public offering in earnest, starting with the selection of underwriters for a KOSDAQ listing in the first half.
"Salted being mentioned as a major player in the smart insole market proves that the direction we have long focused on aligns with market trends," said Cho Hyung-jin, CEO of Salted. "As smart insoles expand beyond sports into medical, rehabilitation, and healthcare applications, we will lead the market through technological advancement and global partnerships."